A poster for Boston Scientific at the American College of Cardiology 2006 Summit in Atlanta. Its stent sales have suffered since studies questioned the safety of drug coatings.
(THOMAS S. ENGLAND/BLOOMBERG NEWS/FILE 2006)
Boston Scientific cuts 8% of staff
Effect on Mass. is unclear; 2,300 jobs slashed worldwide
A poster for Boston Scientific at the American College of Cardiology 2006 Summit in Atlanta. Its stent sales have suffered since studies questioned the safety of drug coatings.
(THOMAS S. ENGLAND/BLOOMBERG NEWS/FILE 2006)
Boston Scientific Corp. , facing flagging sales for its two key product lines, said late yesterday it will eliminate 2,300 jobs, or 8 percent of its worldwide workforce, restructure parts of its business, and go forward with plans to shed some less-critical assets. (Full article: 794 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
